Azithromycin reduces inflammation in a rat model of acute conjunctivitis

Molecular Vision

Volumn 19, Issue , 2013, Pages 153-165

  Fernandez Robredo, Patricia ^a   Recalde, Sergio ^a   Moreno Orduña, Maite ^a   García García, Laura ^a   Zarranz Ventura, Javier ^b   García Layana, Alfredo ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CD69 ANTIGEN; CYCLOOXYGENASE 2; GELATIN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MIGLYOL; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONJUNCTIVA; CONJUNCTIVAL HOMOGENATE; CONJUNCTIVITIS; CONTROLLED STUDY; COX 2 GENE; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUTHANASIA; EYE REDNESS; EYELID EDEMA; GENE EXPRESSION; GOBLET CELL; HISTOPATHOLOGY; IL 6 GENE; IMMUNOFLUORESCENCE; MACROPHAGE; MMP 2 GENE; MMP 9 GENE; MUCUS SECRETION; MULTIPLE CYCLE TREATMENT; NONHUMAN; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; THERAPY EFFECT; TISSUE HOMOGENATE; WESTERN BLOTTING; ZYMOGRAPHY;

ACUTE DISEASE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZITHROMYCIN; CONJUNCTIVITIS; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; GENE EXPRESSION; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873137668     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Cochereau I, Meddeb-Ouertani A, Khairallah M, Amraoui A, Zaghloul K, Pop M, Delval L, Pouliquen P, Tandon R, Garg P, Goldschmidt P, Bourcier T. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol 2007; 91:465-9. [PMID: 17050578.
2. Huguet P, Bella L, Einterz EM, Goldschmidt P, Bensaid P. Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness. Br J Ophthalmol 2010; 94:157-60. [PMID: 19692356.
3. Amza A, Goldschmidt P, Einterz E, Huguet P, Olmiere C, Bensaid P, Bella-Assumpta L. Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops. PLoS Negl Trop Dis 2010; 4:e895. [PMID: 21124889.
4. Zalewska-Kaszubska J, Gorska D. Anti-inflammatory capabilities of macrolides. Pharmacol Res 2001; 44:451-4. [PMID: 11735349].
5. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117:Suppl 9A5S-11S. [PMID: 15586558].
6. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008; 31:12-20. [PMID: 17935949.
7. Merayo-Lloves J, Zhao TZ, Dutt JE, Foster CS. A new murine model of allergic conjunctivitis and effectiveness of nedocromil sodium. J Allergy Clin Immunol 1996; 97:1129-40. [PMID: 8626992.
8. Ekici A, Ekici M, Erdemoglu AK. Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. J Asthma 2002; 39:181-5. [PMID: 11990233.
9. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 2002; 105:1298-303. [PMID: 11901039.
10. Friedlaender MH, Protzko E. Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy. Clin Ophthalmol 2007; 1:3-10. [PMID: 19668461.
11. Merayo-Lloves J, Blanco-Mezquita T, Ibares-Frias L, Cantalapiedra-Rodriguez R, Alvarez-Barcia A. Efficacy and safety of short-duration topical treatment with azithromycin oil-based eyedrops in an experimental model of corneal refractive surgery. Eur J Ophthalmol 2010; 20:979-88. [PMID: 20544676.
12. Utine CA. Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite®) solution in the treatment of ocular infections. Clin Ophthalmol 2011; 5:801-9. [PMID: 21750614.
13. Uriarte SM, Molestina RE, Miller RD, Bernabo J, Farinati A, Eiguchi K, Ramirez JA, Summersgill JT. Effect of macrolide antibiotics on human endothelial cells activated by Chla- mydia pneumoniae infection and tumor necrosis factor-alpha. J Infect Dis 2002; 185:1631-6. [PMID: 12023769.
14. Chung SH, Kweon MN, Lee HK, Choi SI, Yang JY, Kim EK. Toll-like receptor 4 initiates an innate immune response to lipopolysaccharide in human conjunctival epithelial cells. Exp Eye Res 2009; 88:49-56. [PMID: 18951893.
15. Culić O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, Galovic R, Glojnaric I, Manojlovic Z, Munic V, Novak-Mircetic R, Pavicic-Beljak V, Sucic M, Veljaca M, Zanic-Grubisic T, Parnham MJ. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002; 450:277-89. [PMID: 12208321.
16. Robertson MJ, Erwig LP, Liversidge J, Forrester JV, Rees AJ, Dick AD. Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis. Invest Ophthalmol Vis Sci 2002; 43:2250-7. [PMID: 12091424.
17. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125:41S-50S. [PMID: 14872000.
18. Abelson MB, Heller W, Shapiro AM, Si E, Hsu P, Bowman LM. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. Am J Ophthalmol 2008; 145:959-65. [PMID: 18374301.
19. McLean S, Sheikh A. Effectiveness, tolerability and safety of azithromycin 1% in DuraSite for acute bacterial conjunctivitis. Patient Prefer Adherence 2010; 4:69-76. [PMID: 20517467.
20. Robert PY, Bourcier T, Meddeb-Ouertani A, Khairallah M, Zaghloul K, Amraoui A, Bhagat Y, Pop M, Cochereau I. Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis. J Fr Ophtalmol 2010; 33:241-8. [PMID: 20223555].
21. Garnock-Jones KP. Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis. Drugs 2012; 72:361-73. [PMID: 22316352.
22. Sadrai Z, Hajrasouliha AR, Chauhan S, Saban DR, Dastjerdi MH, Dana R. Effect of topical azithromycin on corneal innate immune responses. Invest Ophthalmol Vis Sci 2011; 52:2525-31. [PMID: 21296809.
23. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, Iuvone T, D'Acquisto F, Di Rosa M. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292:156-63. [PMID: 10604943.
24. Amar T, Caillaud T, Elena PP. Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits. Curr Eye Res 2008; 33:149-58. [PMID: 18293185.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54. [PMID: 942051.
26. Fernández-Robredo P, Recalde S, Arnaiz G, Salinas-Alaman A, Sadaba LM, Moreno-Orduna M, Garcia-Layana A. Effect of zeaxanthin and antioxidant supplementation on vascular endothelial growth factor (VEGF) expression in apolipo- protein-E deficient mice. Curr Eye Res 2009; 34:543-52. [PMID: 19899967.
27. Cheung PS, Si EC, Hosseini K. Anti-inflammatory activity of azithromycin as measured by its NF-kappaB, inhibitory activity. Ocul Immunol Inflamm 2010; 18:32-7. [PMID: 20128647.
28. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005; 46:2444-50. [PMID: 15980234.
29. Torkildsen GL, Cockrum P, Meier E, Hammonds WM, Silver-stein B, Silverstein S. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/ blepharoconjunctivitis. Curr Med Res Opin 2011; 27:171-8. [PMID: 21138337.
30. Sato Y, Kaneko K, Inoue M. Macrolide antibiotics promote the LPS-induced upregulation of prostaglandin E receptor EP2 and thus attenuate macrolide suppression of IL-6 production. Prostaglandins Leukot Essent Fatty Acids 2007; 76:181-8. [PMID: 17324565.
31. Bucolo C, Musumeci M, Maltese A, Drago F, Musumeci S. Effect of chitinase inhibitors on endotoxin-induced uveitis (EIU) in rabbits. Pharmacol Res 2008; 57:247-52. [PMID: 18353673.
32. Kim do Y. Jun JH, Lee HL, Woo KM, Ryoo HM, Kim GS, Baek JH, Han SB. N-acetylcysteine prevents LPS-induced pro-inflammatory cytokines and MMP2 production in gingival fibroblasts. Arch Pharm Res 2007; 30:1283-92. [PMID: 18038907.
33. Li DQ, Zhou N, Zhang L, Ma P, Pflugfelder SC. Suppressive effects of azithromycin on zymosan-induced production of proinflammatory mediators by human corneal epithelial cells. Invest Ophthalmol Vis Sci 2010; 51:5623-9. [PMID: 20538995.
34. Corrales RM, de Paiva CS, Li DQ, Farley WJ, Henriksson JT, Bergmanson JP, Pflugfelder SC. Entrapment of conjunctival goblet cells by desiccation-induced cornification. Invest Ophthalmol Vis Sci 2011; 52:3492-9. [PMID: 21421863.
35. Dartt DA, Hodges RR, Li D, Shatos MA, Lashkari K, Serhan CN. Conjunctival goblet cell secretion stimulated by leukotrienes is reduced by resolvins D1 and E1 to promote resolution of inflammation. J Immunol 2011; 186:4455-66. [PMID: 21357260.
36. Bosnar M, Cuzic S, Bosnjak B, Nujic K, Ergovic G, Marjanovic N, Pasalic I, Hrvacic B, Polancec D, Glojnaric I, Haber VE. Azithromycin inhibits macrophage interleukin-1beta production through inhibition of activator protein-1 in lipopolysaccharide-induced murine pulmonary neutrophilia. Int Immunopharmacol 2011; 11:424-34. [PMID: 21195124.